NIH Identifies New Biomarker for Aggressive Breast Cancer Risk and Survival Outcomes

A new study from the National Institutes of Health (NIH) has identified changes in breast connective tissue, called stromal disruption, that could help predict which women are at greater risk of developing aggressive forms of breast cancer or experiencing poorer outcomes. This finding could aid in earlier detection and more tailored treatment strategies, particularly in resource-limited settings.

Using machine learning to analyze more than 9,000 tissue samples—including healthy breast tissue, benign disease biopsies, and invasive breast cancer cases—researchers observed that greater stromal disruption correlated with established risk factors such as younger age, higher number of childbirths, obesity, family history, and self-reported Black race. Among women with benign breast disease, substantial stromal disruption at biopsy was linked with an increased likelihood of developing aggressive breast cancer and a faster disease onset.

In cases of invasive breast cancer, the degree of stromal disruption was associated with more severe cancer types and worse survival rates, especially in estrogen receptor-positive subtypes. This suggests that stromal architecture could serve not only as an early warning indicator for cancer development but also as a marker of prognosis once cancer is diagnosed.

The research team emphasized the potential role of inflammation and wound healing in driving stromal disruption, highlighting possible prevention approaches through lifestyle modification or anti-inflammatory treatments. Because assessing stromal disruption is low-cost and does not require complex molecular testing, it may be particularly useful for identifying high-risk individuals in low-resource settings.

Article by multiple RFHC contributors, based upon information from a press release issued by the National Cancer Institute, part of the National Institutes of Health.

Video Spotlight